This study evaluates whether contrast-enhanced (CE) cardiac magnetic resonance (CMR) can be used to identify critical isthmus sites for ventricular tachycardia (VT) in ischemic and nonischemic heart disease.
aBSTRaCT objective
This study evaluates whether contrast-enhanced (CE) cardiac magnetic resonance (CMR) can be used to identify critical isthmus sites for ventricular tachycardia (VT) in ischemic and nonischemic heart disease.
Background
Fibrosis interspersed with viable myocytes may cause re-entrant VT. CE-CMR has the ability to accurately delineate fibrosis.
Methods
Patients who underwent VT ablation with CE-CMR integration were included. After the procedure critical isthmus sites (defined as sites with a ≥11/12 pacemap, concealed entrainment or VT termination during ablation) were projected on CMR-derived 3D scar reconstructions. The scar transmurality and signal intensity at all critical isthmus, central isthmus and exit sites were compared to the average of the entire scar. The distance to >75% transmural scar and to the core-border zone (BZ) transition was calculated. The area within 5mm of both >75% transmural scar and core-BZ transition was calculated.
Results
In 44 patients (23 ischemic/21 nonischemic, LVEF 44±12%) a total of 110 VTs were induced (CL 290±67ms). Critical isthmus sites were identified for 78 VTs (71%) based on ≥11/12 pacemap (67 VTs) and/or concealed entrainment (10 VTs) and/or termination (30 VTs). The critical isthmus sites, and in particular central isthmus sites, had high scar transmurality and signal intensity compared to the average of the entire scar. Of the pacemap, concealed entrainment and termination sites 74%, 100% and 84% were within 5mm of >75% transmural scar, and 67%, 100% and 94% were within 5mm of core-BZ transition. The areas within 5mm of both >75% transmural scar and core-BZ transition (median 13% of LV) contained all concealed entrainment sites and 77% of termination sites.
Conclusion
Both in ischemic and nonischemic VT, critical isthmus sites are typically located in close proximity to the CMR-derived core-BZ transition and to >75% transmural scar. These findings suggest that CMR-derived scar characteristics may guide to critical isthmus sites during VT ablation.
InTRoDUCTIon
The aim of ventricular tachycardia (VT) ablation is to eliminate critical isthmuses, which can be identified by pacemapping, entrainment mapping and termination of VT by ablation. Applying these techniques is limited by the inducibility of multiple and often hemodynamically untolerated VTs, intramural location of some critical isthmuses, epicardial fat, and other factors.
Fibrotic areas interspersed with viable myocytes can form the substrate for reentrant VTs. Contrast-enhanced (CE) cardiac magnetic resonance (CMR) can accurately delineate areas with dense fibrosis and CE-CMR-derived data have been successfully integrated with electroanatomical maps (EAM) during VT ablation with high registration accuracy. [1] [2] [3] [4] [5] [6] [7] Integrated CE-CMR scar data may guide to the scar area and uncover intramural and subepicardial scars. [1] [2] [3] [4] Although CE-CMR may help to identify scar areas causing VT, there are limited data on specific CMR-derived scar characteristics at critical isthmus sites, which may be useful to guide ablation. Features of interest are scar transmurality, which has been associated with slow conduction , 2, 4, 7, 8 and signal intensity (SI), which has been used to identify conducting channels 5, 6 and to delineate core scar and border zone (BZ). Importantly, to date no study has analyzed the value of CMR-derived scar characteristics to identify areas containing critical isthmuses, thereby potentially guiding substrate-based VT ablation. The aims of the present study are: (1) to assess CMR-derived scar characteristics at critical isthmus sites of ischemic and nonischemic VT and (2) to determine the potential value of CMR to delineate areas containing critical isthmus sites for imaging-guided VT ablation.
MeThoDS

Patients
The study population consisted of 44/48 consecutive patients with prior myocardial infarction (MI, n=23) or nonischemic cardiomyopathy (NICM, n=21) who underwent VT ablation with integration of CE-CMR. Three patients were excluded because of non-interpretable CE-CMR and one because critical isthmus sites could not be reliably identified due to noninducibility of VT.
The diagnosis of prior MI was based on the presence of significant coronary artery disease (≥70% stenosis on coronary angiography) and subendocardial or transmural late gadolinium enhancement (LGE) in a coronary artery perfusion territory. The diagnosis of NICM was based on the exclusion of significant coronary artery disease, congenital heart disease, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardio-myopathy, left ventricular noncompaction, restrictive cardiomyopathy, (sub)acute myocarditis, cardiac sarcoidosis, tachycardia-induced cardiomyopathy and primary valvular abnormalities. All patients were treated according to our standard clinical protocol and provided informed consent.
Ce-CMR acquisition and processing
Contrast-enhanced CMR was performed on a 1.5T Gyroscan ACS-NT/Intera MR system or on a 3.0T Ingenia MR system (Philips Medical Systems, Best, the Netherlands). A standardized protocol was followed, including cine CMR in long-axis (two-and four-chamber views) and short-axis. In addition, the proximal aorta was imaged using a black-blood turbo spin-echo sequence. Contrast-enhanced images were acquired 15min after bolus injection of gadolinium (Magnevist; Schering, Berlin, Germany; 0.15 mmol/kg) with an inversion-recovery 3D turbo-field echo sequence with parallel imaging. The heart was imaged in one or two breath-holds with 20-24 imaging levels in short-axis views.
Using MASS software (research version 2012; LKEB; Leiden University Medical Centre, the Netherlands), the centerline of the proximal coronary arteries and the luminal boundary of the proximal aorta were manually defined in the black-blood spin-echo images. The endocardial and epicardial contours were semi-automatically detected on the short axis images. The defined geometries of the proximal coronary arteries, aorta and myocardial boundaries were converted into 3D meshes. Scar was defined as myocardium with SI ≥35% of maximal myocardial SI, and subdivided into core scar (>50% of maximal SI) and border zone (BZ, 35-50% of maximal SI) according to the method described by Roes et al. 9 . The vertices of the LV endocardial and epicardial meshes were color-coded for scar transmurality for the inner and outer half of the wall, respectively. All meshes were imported into the CARTO system using CARTOMerge (IPE) software. On the CARTO 3 system scars were also visualized as 3-dimensional structures, which were created using MATLAB software (version 2012a).
electrophysiological evaluation
Anti-arrhythmic drugs were discontinued for ≥5 half-lives with the exception of amiodarone. Programmed electrical stimulation consisted of 3 drive cycle lengths (600, 500 and 400ms) with 1-3 ventricular extrastimuli (≥200ms) from ≥2 right ventricular sites and burst pacing (cycle length ≥200ms), which was repeated with isoprenaline (2-10µg/min) when necessary. Positive endpoint for stimulation was induction of a monomorphic VT lasting for >30s or requiring termination because of hemodynamic compromise.
electroanatomical mapping, real-time image integration and ablation
If indicated, epicardial access was first obtained through subxyphoid puncture. Then heparin was administered and EAM was performed using a 3.5mm irrigated-tip catheter (NaviStar ThermoCool, Biosense Webster Inc, Diamond Bar, CA, USA) and the CARTO system. Limited EAM of the aortic root was performed and the position of the left main coronary artery, confirmed by contrast injection through the mapping catheter, was tagged on the map. CE-CMR-derived images were visually aligned with the EAM using the left main landmark. Then, the LV was mapped retrogradely focusing on the integrated CMR-derived scar. The LV surfaces of CMR and EAM were aligned with the translation tool provided by the mapping system, until the lowest mean surface registration error was reached. Multidetector computed tomography-derived coronary artery anatomy and epicardial fat meshes were integrated with the EAM in patients undergoing epicardial mapping. 4, 10 Potential ablation target sites were identified by activation mapping and entrainment mapping for stable VT. For unstable VT, the area of interest was identified by substrate mapping and detailed pacemapping. To confirm the best pacemap site, pacing was repeated after moving the catheter in all possible directions. With the catheter placed in the area of interest, VT was reinduced and briefly mapped to identify diastolic activity and terminate the VT by ablation, also for hemodynamically unstable VT.
At the epicardium, ablation was usually withheld when the estimated distance to a coronary artery was <5mm, as assessed by integrated multidetector computed tomography-derived coronary anatomy and coronary angiography. 10 High output pacing (10mA, 2ms) was performed to localize the phrenic nerve. Radiofrequency energy was applied at 30-45W (maximum temperature 45°C, flow 20-30ml/min, 60s) for endocardial sites and ≤50W (flow 20ml/min) for epicardial sites.
acute and long-term outcome
After ablation, the entire programmed electrical stimulation protocol was repeated. Isoprenaline was administered if required to induce VT before ablation. Complete procedural success was defined as non-inducibility of any sustained monomorphic VT; partial success as elimination of the (presumed) clinical VT but persistent inducibility of ≥1 nonclinical VT; failure as persistent inducibility of the (presumed) clinical VT. Patients were followed at 3, 6 and 12 months after ablation and at 6-to 12-monthly intervals thereafter.
Critical isthmus sites
For the current analysis all studies were thoroughly reviewed on the electrophysiology recording system (Prucka Cardiolab recording system, Houston, TX, USA) while the observer was blinded to the electroanatomical maps. Critical isthmus sites were defined by the following criteria:
(1) ≥11/12 pacemap (precise match of major deflections and all subtle notches in ≥11/12 leads; site with longest S-QRS delay in case of identical match) and/or (2) concealed entrainment with post-pacing interval equal to tachycardia cycle length and/or (3) VT slowing and termination during ablation. Critical isthmus sites for the same VT could be identified by more than one criterion. Because of differences in accuracy between pacemapping, entrainment and termination, we have stratified the analysis for these different criteria. Critical isthmus sites were further subdivided into central isthmus sites (S-QRS or E-QRS 31-70% of VT cycle length) and exit sites (S-QRS or E-QRS 0-30% of VT cycle length).
The LV endocardial low bipolar (≤1.50mV) and unipolar (≤8.27mV 11 ) voltage areas were measured in all patients, and the epicardial low bipolar (≤1.81mV 4 ) and unipolar (≤7.95mV 4 ) voltage areas were measured in patients with NICM who underwent epicardial mapping. The location of LV endocardial critical isthmus sites with respect to the endocardial low voltage areas was assessed in all patients. The location of LV epicardial critical isthmus sites with respect to epicardial areas with low voltage and abnormal electrograms 4 was assessed in patients with NICM.
Contrast-enhanced CMR-derived 3D scar reconstructions
CMR-derived 3D scar reconstructions and all CMR-based scar parameters were computed using MATLAB software. Examples of scars are displayed in Figures 1 and 2 . After the procedure, all mapping points at critical isthmus sites were projected onto the CMR-derived 3D scar reconstructions using MATLAB software (example in Figure 2 ). Scar transmurality was calculated by dividing scar thickness by wall thickness. The local scar transmurality and SI at a mapping point were calculated as the mean value within a 5mm-radius transmural cylinder around the mapping point. The local scar transmurality and SI at critical isthmus sites were compared to the average scar transmurality and SI in the same patient. The distances from critical isthmus sites to >75% transmural scar and core-BZ transition were calculated. The core-BZ transition was defined as the line where core and BZ meet, projected on the endocardial or epicardial surface.
The following predefined areas were calculated for the endocardium and epicardium in each patient: CMR-derived scar, area within 5mm of >75% transmural scar, area within 5mm of core-BZ transition, and areas within 5mm and 10mm of the core-BZ transition with >75% scar transmurality. The percentage of critical isthmus sites located within these areas was calculated.
CMR-derived overall scar characteristics were calculated, including total scar volume, core volume, BZ volume and areas of ≤50%, 51-75% and >75% transmural scar. The relation between these characteristics and (1) average cycle length of induced VTs, (2) number of induced VTs, (3) inducibility of VT after ablation and (4) VT recurrence was assessed.
Statistical analysis
Categorical variables are displayed as number (percentage) and continuous variables are expressed as mean±standard deviation or median (interquartile range [IQR] ). Continuous variables were compared using the Student's t test when normally distributed or the Mann-Whitney U test when non-normally distributed. For paired variables, the paired t test or the Wilcoxon signed-rank-test were used, respectively. The relation between CMR-derived overall scar characteristics and the number of induced VTs and average cycle length of induced VTs was fi rst analyzed by univariate linear regression analysis. The relation with VT inducibility after ablation was analyzed by univariate logistic regression and the relation with VT recurrence by univariate Cox regression. When statistically signifi cant associations were identifi ed in univariate analyses, multivariate analyses were performed to assess the independent associations between the scar characteristics of interest and the VT or outcome parameters. All analyses were performed with SPSS version 20.0 (IBM, Somers, New York, USA). All tests are two-sided and p-values <0.05 were considered signifi cant.
ReSULTS
A total of 44 patients (23 post-MI/21 NICM, age 62±13 years, CMR-based LVEF 44±12%) underwent VT ablation with integration of CMR-derived scar (178±76 LV mapping points; average registration error 3.8±0.6mm, example in Figure 1 ). Epicardial mapping was performed in 15 patients (13 NICM, 2 post-MI; 174±99 mapping points). Baseline and procedural data are provided in Table 1 . A total of 110 distinct VTs (cycle length 290±67ms) could be induced during the procedure. A ≥11/12 pacemap was obtained in 67 VTs (61%; median S-QRS 30ms, IQR 10-48ms). Entrainment was concealed with Area of 51-75% transmural scar, % 7 (4-10) 9 (5-12) 6 (4-9)
Area of >75% transmural scar, % 6 (3-10) 7 (3-13) 4 (2-7)
BMI indicates body mass index; BZ, border zone; eGFR, estimated glomerular filtration rate; LV, left ventricular; NYHA, New York heart association; VT, ventricular tachycardia post-pacing interval equaling VT cycle length in 10 VTs (9%; median E-QRS 98ms, IQR 61-133ms). Thirty-one VTs (28%) slowed and terminated during ablation (median E-QRS before ablation 96ms, IQR 37-126ms; median time to termination 9sec, IQR 6-11sec). Based on these findings, critical isthmus sites could be identified in 78 of 110 VTs (71%) at the following locations: LV endocardium (46 VTs, 59%), epicardium (16 VTs, 21%), right ventricular septum (7 VTs, 9%), aortic root (5 VTs, 6%), both aortic root and LV endocardium (2 VTs, 3%), both right ventricular endocardium and epicardium (1 VT, 1%) and anterior cardiac vein (1 VT, 1%). Complete procedural success was achieved in 26 patients (59%), partial success in 9 (21%), failure in 5 (11%), and the acute outcome was indeterminate in 4 (9%) due to non-inducible clinical VT prior to ablation.
Scar transmurality, signal intensity and distance to core-BZ transition at critical isthmus sites
The mapping points at critical isthmus sites were successfully projected on the CE-CMRderived 3D scar reconstructions (examples in Figure 2 ). One epicardial VT originated from the right ventricular outflow tract and was excluded from further analyses. Sites with a ≥11/12 pacemap had a scar transmurality of 66±22%, compared with an average scar transmurality in the same patients of 59±12% (p=0.005, Figure 3) . The difference in transmurality was larger at concealed entrainment sites (concealed entrainment 76±16% vs. average 62±10%, p=0.024) and termination sites (termination 70±21% vs. average 62±12%, p=0.018).
The scar SI at critical isthmus sites was higher than the average scar SI in the same patients (≥11/12 pacemap 68±24% vs. average 59±16%, p=0.001; concealed entrainment 72±21% vs. average 58±15%, p=0.074; termination 69±21% vs. average 59±15%, p=0.010; Figure 3) .
The median distance to >75% transmural scar was 1.5mm (IQR, 0.0-5.6mm) at ≥11/12 pacemaps, 0.0mm (IQR, 0.0-3.0mm) at concealed entrainment sites and 1.8mm (IQR, 0.0-3.8mm) at termination sites (Figure 4) . The critical isthmus sites clustered around the core-BZ transition, with a median distance to the transition of 3.7mm (IQR, 1.5-7.0mm) at ≥11/12 pacemaps, 1.9mm (IQR, 0.0-2.6mm) at concealed entrainment sites and 2.5mm (IQR, 1.1-4.2mm) at termination sites.
Scar characteristics at exit and isthmus sites
Based on pacemapping, exit sites could be identified in 60 VTs and central isthmus sites in 6 VTs. Scar transmurality and SI were higher at pacemapping-based central isthmus and exit sites, compared to the average ( Figure 5 ). The differences were more pronounced at central isthmus sites (transmurality 78±14% vs. average 64±8%, p=0.051; SI 77±17% vs. average 59±6%, p=0.012), than at exit sites (transmurality 65±23% vs. average 59±12%, p=0.019; SI 67±25% vs. average 59±17%, p=0.004).
Of the 31 termination sites, 16 (52%) were consistent with an exit site and 15 (48%) with a central isthmus site. Scar transmurality was above average at central isthmus sites (75±22% vs. 60±13%, p=0.008), but not at exit sites (66±19% vs. 63±10%, p=0.58). Similarly, SI was above average at central isthmus sites (74±21% vs. 56±13%, p=0.006), but not at exit sites (65±21% vs. 62±15%, p=0.54). The number of concealed entrainment sites was too small for subgroup analyses.
nonischemic cardiomyopathy vs. post-myocardial infarction
At ≥11/12 pacemaps and termination sites, the CMR-derived scar characteristics (including scar transmurality, SI, distance to >75% transmural scar and distance to core-BZ transition) were not significantly different between patients with NICM or prior MI (all p>0.05, data not shown).
CMR-based identification of critical isthmus sites
The CMR-derived scar area (median 24% of LV, IQR 16-30%) contained 77% of ≥11/12 pacemap sites, 90% of concealed entrainment sites and 90% of termination sites ( Figure  6A ). The area within 5mm of both >75% transmural scar and core-BZ transition (median 13% of LV, IQR 7-19%) included only 56% of ≥11/12 pacemap sites, but still 100% of concealed entrainment sites and 77% of termination sites. In post-MI patients the areas within 5mm of >75% transmural scar, within 5mm of the core-BZ transition and the low bipolar voltage areas were limited in size and contained the majority of LV endocardial critical isthmus sites ( Figure 6B ).
For patients with NICM the areas within 5mm of both >75% transmural scar and core-BZ transition (median 13% of LV, IQR 6-19%), and the LV endocardial low unipolar voltage area (median 11% of LV, IQR 2-16%) were comparably small and contained the majority of LV endocardial critical isthmus sites ( Figure 6C ). The LV epicardial low bipolar and unipolar voltage areas with abnormal electrograms were large (median 27% of LV, IQR 15-41% and median 43% of LV, IQR 25-65%, respectively), while the area within 5mm of both >75% transmural scar and core-BZ transition was smaller (median 12% of LV, IQR 6-19%) and contained the majority of epicardial entrainment and termination sites ( Figure 6D ).
CMR-derived scar characteristics, VT characteristics and outcome
Univariate analysis revealed that total scar, core and BZ volumes, and areas of 51-75% and >75% transmural scar were associated with slower induced VTs (supplemental Table  1 ). In a multivariate model including scar transmurality areas, only the area of >75% transmural scar remained associated with VT cycle length (+17ms per 5cm 2 , 95% confidence interval 7-27ms, p=0.001). In a multivariate model including the core and BZ volumes, only the BZ volume remained associated with VT cycle length (+20ms per 5mL BZ, 95% confidence interval 9-32ms, p=0.001). BZ volume and area of >75% transmural scar were interrelated (R 2 0.50, p<0.001) and became non-significant if both parameters were included in a model. None of the overall scar characteristics were associated with the number of induced VTs, inducibility of VT after ablation, or VT recurrence (all p>0.20, supplemental Tables 2-4) . 
DISCUSSIon
In the present study critical VT isthmus sites in patients with prior MI or NICM were typically located in close proximity to the CMR-derived core-BZ transition and >75% transmural scar. In particular central isthmus sites had high scar transmurality and signal intensity compared to the average of the entire scar, suggesting that slow conducting pathways are located within relatively dense and transmural scar. The area within 5mm of both >75% transmural scar and the core-BZ transition covered a median of 13% of the LV, but contained all concealed entrainment sites and 77% of VT termination sites, allowing CE-CMR-based delineation of relatively small areas containing critical parts of the reentry circuit. The BZ volume and area of >75% transmural scar were positively correlated with the cycle length of induced VTs, providing further support to the premise that the BZ and >75% transmural scar are associated with slow conduction.
Scar transmurality and signal intensity
The current study comprises the largest series of patients undergoing VT ablation with CE-CMR-integration to date, and provides detailed analyses of CMR-derived scar parameters at VT-related sites. Critical isthmus sites were typically located within, or in close proximity to, >75% transmural scar in post-MI and NICM patients. In one prior study in 23 post-MI patients, 62% of reentrant VT critical sites were identified in regions with >75% transmural scar 8 . Several studies have demonstrated a strong correlation between electrogram prolongation and scar transmurality 2, 4, 7, 8 , which is in line with our finding that the area of >75% transmural scar correlated positively with the cycle length of induced VTs. Scar transmurality may therefore be an important aspect of the substrate for reentrant VT.
The scar density at critical isthmus sites is reported in only one study in 9 patients with ischemic VT, in which 71% of VT isthmus sites were located in the infarct core and 29% in the BZ. 7 All critical sites in the BZ were in an area of transmural infarct, with SI slightly lower than the cutoff defining core infarct. In the present study, the remarkable bell-shaped distribution of critical isthmus sites around the core-BZ transition suggests that the 50% of maximal SI threshold may indicate a critical mix between fibrosis and viable myocytes that allows for slow conduction and thereby, reentrant VT. CMR-derived BZ channels through higher SI scar areas have been correlated with critical isthmus sites. 5, 6, 12 Notably, in the present study we observed relatively high SI at critical isthmus sites, contradicting the premise that VT isthmuses manifest as relatively low SI channels on CE-CMR. Prior investigations demonstrated differences in scar features between patients with NICM and prior MI. One study demonstrated a lower LGE SI in patients with atypical LGE patterns, compared to patients with infarct LGE pattern, suggesting a higher scar den-sity in post-MI patients. 13 A study in 33 patients with NICM or prior MI who underwent VT ablation showed that patients after MI had more pronounced EAM-based conduction delay than patients with NICM. 14 In the current study we could demonstrate that, although overall scar characteristics may be different, CMR-derived scar characteristics at critical isthmus sites were similar between patients with prior MI or NICM.
CMR-based identification of the area of interest
We could demonstrate the added value of CMR-based scar characteristics for identification of areas containing critical isthmus sites during VT ablation. A limited area within 5mm of both >75% transmural scar and core-BZ transition encompassed all concealed entrainment sites and 77% of termination sites, which are considered to be reliable markers for critical isthmus sites. This area may therefore serve as a target area for substrate-guided ablation approaches. Only 56% of ≥11/12 pacemap sites was located in these regions. However, ≥11/12 pacemaps may also be recorded in the vicinity of exit sites and may therefore be less accurate. Importantly, the CMR-derived target area can be displayed and used as a guide for ablation using single landmark-based image integration without extensive electroanatomical substrate mapping.
Limitations
No critical isthmus sites could be identified in 29% of VTs, which may be due to intramural reentry circuits, epicardial reentry circuits in patients who did not undergo epicardial mapping, or epicardial reentry circuits that could not be mapped due to epicardial fat. Pacemapping is considered to be a less accurate technique for defining critical isthmus sites, in particular if no S-QRS delay is observed. Therefore we have stratified the analysis for different techniques to identify critical isthmus sites and for different E/S-QRS delays.
Scar transmurality and signal intensity were calculated for a 5mm-radius transmural cylinder and therefore, they do not depend on the endocardial or epicardial location. The present data can thus not be used to predict whether an endocardial or epicardial ablation procedure will be successful.
Data from endocardial and epicardial critical isthmus sites were pooled, since the distance to >75% transmural scar and core-BZ transition did not differ between endocardial and epicardial pacemapping-based or termination-based critical isthmus sites in patients with NICM.
Clinical implications
Based on the present findings, CMR may be used to guide to areas that are likely to contain critical isthmus sites. Within these areas, ablation target sites may be further specified (e.g., based on electrogram characteristics or pace-mapping). Importantly, the CMR-derived area of interest is available before extensive substrate mapping and not limited by intramural or subepicardial location of scars, or by epicardial fat. Moreover, it is relatively small compared to low voltage areas, in particular to epicardial low voltage areas in NICM. VT cycle length was not different between VTs with and without an identifiable critical isthmus site (294±65ms vs. 282±70ms, p=0.40), indicating that both slow and fast VTs are represented in the analysis. CMR may be particularly useful if no or only limited mapping time is available for poorly tolerated fast VT. Future prospective studies are required to assess whether CMR guidance to preselected regions that are likely to contain critical isthmus sites may improve the efficiency and efficacy of VT ablation.
ConCLUSIon
In ischemic and nonischemic VT, critical parts of the reentry circuit are typically located in close proximity to >75% transmural scar and the core-BZ transition. The area within 5mm of both >75% transmural scar and core-BZ transition contained all concealed entrainment sites and 77% of termination sites. These findings suggest that CMR-derived scar characteristics may be used to guide to critical isthmus sites during VT ablation. 
